Sanofi Earnings Reports

Sanofi delivered profitable growth in Q3 2025, with business EPS reaching €2.91 and total revenue of €12.43 billion. Net income remained stable, while Dupixent sales exceeded €4 billion for the first time. Vaccine sales declined due to flu-related weakness.

Sanofi delivered a solid Q2 2025 with 10.1% constant exchange rate sales growth and strong contributions from new product launches and immunology. Business EPS rose to €1.59, and net income more than tripled to €3.94 billion.

Sanofi delivered a solid Q1 2025 performance with 10.8% revenue growth and a 17% increase in non-GAAP EPS, supported by strong momentum in its pharma pipeline and immunology portfolio.